Alimera Sciences News
Alimera Sciences, Inc. (ALIM) Posts Q1 Loss of 27c/Share
Street Insider May 9Alimera Sciences Reports First Quarter 2013 Financial Results
PR Newswire May 9ATLANTA, May 9, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic ...
Alimera Sciences Secures $20 Million Debt Facility
PR Newswire May 8ATLANTA, May 8, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic ...
Alimera Sciences Announces First Patient Treated With Commercially Available ILUVIEN®
PR Newswire May 7ATLANTA, May 7, 2013 /PRNewswire/-- Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic ...
Alimera Sciences To Release First Quarter Fiscal Year 2013 Financial Results
PR Newswire May 3ATLANTA, May 3, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ...
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ALIM | 4.29 | -0.09 | -2.05% | 135.38M |
